Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 166 of the 175 references it cites were found in a registry or an index; 46 of the 94 sources its claims cite were checked for support.

ROS in cancer therapy: the bright side of the moon

Open access
Perillo, Bruno, Di Donato, Marzia, Pezone, Antonio, Di Zazzo, Erika, Giovannelli, Pia, Galasso, Giovanni, Castoria, Gabriella, Migliaccio, Antimo · 2020 · Experimental & Molecular Medicine

Abstract

Reactive oxygen species (ROS) constitute a group of highly reactive molecules that have evolved as regulators of important signaling pathways. It is now well accepted that moderate levels of ROS are required for several cellular functions, including gene expression. The production of ROS is elevated in tumor cells as a consequence of increased metabolic rate, gene mutation and relative hypoxia, and excess ROS are quenched by increased antioxidant enzymatic and nonenzymatic pathways in the same cells. Moderate increases of ROS contribute to several pathologic conditions, among which are tumor promotion and progression, as they are involved in different signaling pathways and induce DNA mutation. However, ROS are also able to trigger programmed cell death (PCD). Our review will emphasize the molecular mechanisms useful for the development of therapeutic strategies that are based on modulating ROS levels to treat cancer. Specifically, we will report on the growing data that highlight the role of ROS generated by different metabolic pathways as Trojan horses to eliminate cancer cells.

Overview

CoChat Summary

## TL;DR

This review argues that reactive oxygen species (ROS) have a dual role in cancer: they can promote tumor initiation and progression at moderate levels, but they can also be exploited therapeutically to push cancer cells into death pathways. It highlights multiple ROS-based anticancer strategies, including drugs and combinations that raise ROS beyond a threshold cancer cells can tolerate.

## Key findings

  • Cancer cells typically maintain ROS at moderately elevated levels and rely on enhanced antioxidant systems; the paper argues this creates a therapeutic vulnerability that can be exploited by further increasing ROS to induce oxidative stress incompatible with cell survival.
  • ROS are linked to multiple cancer-relevant processes, including DNA damage and mutation, chromatin/epigenetic changes, HIF1α activation, proliferation, invasion, EMT, metastasis, and multidrug resistance.
  • The review states that ROS can induce several forms of programmed cell death, including apoptosis, autophagy, necroptosis, and ferroptosis, and gives examples of therapies that act through these mechanisms, such as imatinib, erlotinib, vemurafenib, rituximab, doxorubicin, arsenic trioxide, and photodynamic therapy.
  • It notes specific quantitative observations from prior studies: each cell is exposed to about ~1.5 × 10^5 oxidative hits per day, and ~1 in 10^5 guanines is oxidized in normal cells, increasing by 35–50% in transformed cells.

## Methods

  • Not an original study; this is a narrative review of the literature on ROS biology in cancer and ROS-based anticancer strategies.
  • The paper synthesizes previously published findings on ROS generation, signaling, DNA damage, cell death pathways, antioxidant defenses, and therapeutic examples across cancer types.
  • Main analysis is conceptual and integrative, organizing evidence by biological outcome and therapeutic mechanism rather than reporting a new dataset.

## Limitations

  • The paper itself states that although many studies suggest benefits of antioxidant drugs in cancer therapy, “none has been supported by solid trials performed on a large scale.”
  • It also states that more studies are required to increase the selectivity of ROS-related anticancer drugs.
  • Evident from the text: this is a review, so its conclusions depend on heterogeneous prior studies rather than direct experimental validation in a single dataset.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s12276-020-0384-2

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Redox signaling and oxidative stress in normal and cancer cells. The major signaling cascades induced by growth factor-stimulated ROS are highlighted on the left. The same pathways influence the cell cycle and affect the activity of transcription factors and genes that play roles in the cellular response to the hypoxic microenvironment. ROS also induce lipid peroxidation with commensurate electron leakage in mitochondria and the release of Ca2+ from intracellular stores. The main consequences of oxidative stress in cancer cells are illustrated on the right. Moderately elevated ROS induce oncogenes and inhibit tumor suppressor genes that, in turn, increase ROS levels. Ca2+ release induces PKC, while the expression of genes involved in the formation of new blood vessels and in the establishment of a boosted antioxidant system is enhanced. ROS also activate HDACs and have a dual effect on DNMTs with important outcomes for the expression of oncogenes and tumor suppressor genes. Oxidized bases trigger mutations and engage DNA repair enzymes.
Fig. 1 Redox signaling and oxidative stress in normal and cancer cells. The major signaling cascades induced by growth factor-stimulated ROS are highlighted on the left. The same pathways influence the cell cycle and affect the activity of transcription factors and genes that play roles in the cellular response to the hypoxic microenvironment. ROS also induce lipid peroxidation with commensurate electron leakage in mitochondria and the release of Ca2+ from intracellular stores. The main consequences of oxidative stress in cancer cells are illustrated on the right. Moderately elevated ROS induce oncogenes and inhibit tumor suppressor genes that, in turn, increase ROS levels. Ca2+ release induces PKC, while the expression of genes involved in the formation of new blood vessels and in the establishment of a boosted antioxidant system is enhanced. ROS also activate HDACs and have a dual effect on DNMTs with important outcomes for the expression of oncogenes and tumor suppressor genes. Oxidized bases trigger mutations and engage DNA repair enzymes.CC BY · PubMed Central
Fig. 2 The three types of programmed cell death induced by elevated ROS levels in cancer cells. ROS, in response to death-inducing ligands (TNFα and Fas), enhance the assembly of DISCs and the activation of effector caspases and reduce Bcl-2 activity or, as a consequence of increased permeability of mitochondrial PTPs, stimulate the intracytoplasmic release of cytochrome c, which interacts with Apaf-1 and procaspases and forms the apoptosome (apoptosis). ROS can also inhibit the negative regulators of autophagy (TORC1) and increase the formation of LC3-dependent autophagosomes (autophagy). Finally, high levels of ROS, induced by several receptor-interacting protein kinases (RIPs), increase p53 expression, which increases ROS levels via a mechanism that depends on intracellular iron (ferroptosis).
Fig. 2 The three types of programmed cell death induced by elevated ROS levels in cancer cells. ROS, in response to death-inducing ligands (TNFα and Fas), enhance the assembly of DISCs and the activation of effector caspases and reduce Bcl-2 activity or, as a consequence of increased permeability of mitochondrial PTPs, stimulate the intracytoplasmic release of cytochrome c, which interacts with Apaf-1 and procaspases and forms the apoptosome (apoptosis). ROS can also inhibit the negative regulators of autophagy (TORC1) and increase the formation of LC3-dependent autophagosomes (autophagy). Finally, high levels of ROS, induced by several receptor-interacting protein kinases (RIPs), increase p53 expression, which increases ROS levels via a mechanism that depends on intracellular iron (ferroptosis).CC BY · PubMed Central
Fig. 3 Role of nuclear ROS in transcription and DNA damage. ROS generated during nuclear receptor-induced transcription of target genes by the activity of lysine demethylases on lysine 9 in histone H3 must be controlled to prevent their accumulation. To this end, SOD1 reaches the nuclear space, while phosphorylation of H3S10 inhibits the rapid remethylation of the same lysine. If inhibitors of the H3S10 kinases are introduced as a Trojan horse together with nuclear receptor ligands, remethylation of H3K9 is quick, nuclear ROS accumulate, and unrepaired DNA damage triggers PCD.
Fig. 3 Role of nuclear ROS in transcription and DNA damage. ROS generated during nuclear receptor-induced transcription of target genes by the activity of lysine demethylases on lysine 9 in histone H3 must be controlled to prevent their accumulation. To this end, SOD1 reaches the nuclear space, while phosphorylation of H3S10 inhibits the rapid remethylation of the same lysine. If inhibitors of the H3S10 kinases are introduced as a Trojan horse together with nuclear receptor ligands, remethylation of H3K9 is quick, nuclear ROS accumulate, and unrepaired DNA damage triggers PCD.CC BY · PubMed Central
Fig. 4 The two possible ROS-related anticancer therapeutic strategies. The first approach is based on lowering ROS levels to counteract their role in cellular transformation; it is aimed at reducing the number of transformed cells by depriving them of fuel (represented in the upper right side of the figure as a lower proportion of transformed cells with respect to that of normal cells). The second approach is based on the consideration that cancer cells, with an antioxidant system already triggered, are more sensitive than their normal counterparts to further increases in ROS and are unable to achieve redox balance. Therefore, by inducing ROS under these metabolic conditions, a high percentage of the cells undergo death (represented in the lower right side of the figure, where transformed cells are depicted as apoptotic).
Fig. 4 The two possible ROS-related anticancer therapeutic strategies. The first approach is based on lowering ROS levels to counteract their role in cellular transformation; it is aimed at reducing the number of transformed cells by depriving them of fuel (represented in the upper right side of the figure as a lower proportion of transformed cells with respect to that of normal cells). The second approach is based on the consideration that cancer cells, with an antioxidant system already triggered, are more sensitive than their normal counterparts to further increases in ROS and are unable to achieve redox balance. Therefore, by inducing ROS under these metabolic conditions, a high percentage of the cells undergo death (represented in the lower right side of the figure, where transformed cells are depicted as apoptotic).CC BY · PubMed Central

Verification

Claims the paper makes

30 Valid · 2 Not valid · 26 Not checked · 1 Own results and interpretations

25 more claims · 10 with their cited sources checked

Create a free account to see all 59 claims and to verify the 8 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 175 references

Cited by

See all 2,176

Metadata

Authors
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A.
Affiliations
  • Institute of Food Science (IT)
  • University of Naples Federico II (IT)
  • University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Perillo, Bruno
Venue
Experimental & Molecular Medicine
Published
2020-02
Volume
52
Issue
2
Pages
192-203
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W3005689864
Cited by
2,176
References
175
Citations by year
2026: 188 · 2025: 348 · 2024: 383 · 2023: 434 · 2022: 459 · 2021: 282 · 2020: 80
FWCI
30.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
  • Fondazione Umberto Veronesi
  • Regione Calabria
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
reactive oxygen species, cancer therapy, tumor hypoxia, antioxidant enzymes, tumor progression, DNA mutations, programmed cell death, metabolic pathways, cancer metabolism
MeSH terms
DNA, Humans, Mutation, Neoplasms, Signal Transduction, Reactive Oxygen Species, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ROS in cancer therapy: the bright side of the moon. https://app.cochat.ai/papers/10.1038/s12276-020-0384-2
The paper
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020). ROS in cancer therapy: the bright side of the moon. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-020-0384-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.